Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies.

Fujimi A, Sakamoto H, Kanisawa Y, Minami S, Nagamachi Y, Yamauchi N, Ibata S, Kato J.

Clin J Gastroenterol. 2016 Dec;9(6):358-364. Epub 2016 Sep 16. Review.

PMID:
27638345
2.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
3.

[A Case of Chronic Myelogenous Leukemia That Developed Fibrous Pericarditis Owing to Nilotinib Use].

Miura S, Murase K, Sakurada A, Takada K, Iyama S, Sato T, Sato Y, Miyanishi K, Kobune M, Muranaka A, Tachibana K, Kato J.

Gan To Kagaku Ryoho. 2017 Jun;44(6):529-531. Japanese.

PMID:
28698448
4.

A severe case of pneumatosis cystoides intestinalis with massive accumulation of gas outside the gastrointestinum.

Tatò F, Mack M, Meissner O, Schlöndorff D.

Z Gastroenterol. 2001 Sep;39(9):797-800.

PMID:
11558072
5.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
6.

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.

Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia M, Salvucci M, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F, Bocchia M.

Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19.

7.

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.

Fullmer A, Kantarjian H, Cortes J, Jabbour E.

Expert Opin Pharmacother. 2010 Dec;11(18):3065-72. doi: 10.1517/14656566.2010.535655. Epub 2010 Nov 13. Review.

PMID:
21073351
8.

Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Nicolini FE, Turkina A, Shen ZX, Gallagher N, Jootar S, Powell BL, De Souza C, Zheng M, Szczudlo T, le Coutre P.

Cancer. 2012 Jan 1;118(1):118-26. doi: 10.1002/cncr.26249. Epub 2011 Jul 5.

9.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P.

Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.

10.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.

Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.

J Med Econ. 2017 Apr;20(4):328-336. doi: 10.1080/13696998.2016.1261032. Epub 2016 Dec 2.

PMID:
27841717
11.

Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.

Nagai T, Karakawa M, Komine M, Muroi K, Ohtsuki M, Ozawa K.

Eur J Haematol. 2013 Sep;91(3):270-2. doi: 10.1111/ejh.12153. Epub 2013 Jun 28.

PMID:
23734955
12.

Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.

Kaune KM, Baumgart M, Gesk S, Mitteldorf C, Baesecke J, Glass B, Haase D, Siebert R, Ghadimi BM, Neumann C, Emmert S.

Arch Dermatol. 2008 Mar;144(3):361-4. doi: 10.1001/archderm.144.3.361.

PMID:
18347292
13.

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A.

J Clin Oncol. 2009 Sep 1;27(25):4204-10. doi: 10.1200/JCO.2009.21.8230. Epub 2009 Aug 3.

14.

Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.

Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M.

Cancer Treat Rev. 2012 May;38(3):241-8. doi: 10.1016/j.ctrv.2011.07.004. Epub 2011 Aug 12. Review.

PMID:
21840128
15.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A.

Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11.

16.

Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.

Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, Rowe JM, Schwarz M, Goldschmidt N, Nagler A.

Cancer. 2010 Oct 1;116(19):4564-72. doi: 10.1002/cncr.25351. Erratum in: Cancer. 2011 Jan 1;117(1):230.

17.

[Nilotinib in patients with chronic myeloid leukemia without response to imatinib].

Báez-de la Fuente E, Arellano-Severiano B.

Rev Med Inst Mex Seguro Soc. 2014 May-Jun;52(3):330-3. Spanish.

PMID:
24878095
18.

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H.

IDrugs. 2007 Jul;10(7):468-79.

PMID:
17642017
19.

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Jarkowski A, Sweeney RP.

Pharmacotherapy. 2008 Nov;28(11):1374-82. doi: 10.1592/phco.28.11.1374. Review.

PMID:
18956997
20.

[A sixty-year-old man suffering from multiple system atrophy with pneumatosis intestinalis].

Shimizu F, Kawai M, Ogasawara J, Negoro K, Kanda T.

Rinsho Shinkeigaku. 2007 Jan;47(1):47-9. Japanese.

PMID:
17491337

Supplemental Content

Support Center